Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

N5260

Sigma-Aldrich

(−)-Nicotine hydrogen tartrate salt

≥98% (TLC), powder

Sinonimo/i:

(−)-1-Methyl-2-(3-pyridyl)pyrrolidine (+)-bitartrate salt

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C10H14N2 · 2C4H6O6
Numero CAS:
65-31-6
Peso molecolare:
462.41
Numero CE:
200-607-2
Codice UNSPSC:
12352200
ID PubChem:
24278591

Saggio

≥98% (TLC)

Forma fisica

powder

Colore

white to off-white

Solubilità

H2O: 50 mg/mL

Stringa SMILE

CN1CCC[C@H]1C2=CC=CN=C2.C

InChI

1S/C10H14N2.CH4/c1-12-7-3-5-10(12)9-4-2-6-11-8-9;/h2,4,6,8,10H,3,5,7H2,1H3;1H4/t10-;/m0./s1
RYYKFQGHMYGLEL-PPHPATTJSA-N

Informazioni sul gene

human ... CHRNA1(1134) , CHRNA10(57053) , CHRNA2(1135) , CHRNA3(1136) , CHRNA4(1137) , CHRNA5(1138) , CHRNA6(8973) , CHRNA7(1139) , CHRNA9(55584) , CHRNB1(1140) , CHRNB2(1141) , CHRNB3(1142) , CHRNB4(1143)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Azioni biochim/fisiol

Prototype nicotinic acetylcholine receptor agonist; naturally occurring isomer.

Avvertenze

Danger

Indicazioni di pericolo

H301,H319,H330,H361d,H411

Classi di pericolo

Acute Tox. 2 Inhalation - Acute Tox. 3 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Repr. 2

Codice della classe di stoccaggio

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

289.8 °F

Punto d’infiammabilità (°C)

143.2 °C

Dispositivi di protezione individuale

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 4

1 of 4

(−)-Nicotine solution 1.0 mg/mL, analytical standard, for drug analysis

Supelco

N5511

(−)-Nicotine solution

Nicotine for system suitability European Pharmacopoeia (EP) Reference Standard

Y0001023

Nicotine for system suitability

(−)-Nicotine PESTANAL®, analytical standard

Supelco

36733

(−)-Nicotine

(-)-Nicotine for synthesis

Sigma-Aldrich

8.20877

(-)-Nicotine

Song Xue et al.
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 22(2), 172-179 (2018-11-20)
Tobacco is highly addictive, and after the development of dependence, it is difficult to quit smoking. Therefore, it is important to understand the factors that play a role in the initiation of smoking. The rewarding effects of nicotine play a
Jhodie R Duncan et al.
Journal of applied physiology (Bethesda, Md. : 1985), 107(5), 1579-1590 (2009-09-05)
During pregnancy, exposure to nicotine and other compounds in cigarette smoke increases the risk of the sudden infant death syndrome (SIDS) two- to fivefold. Serotonergic (5-HT) abnormalities are found, in infants who die of SIDS, in regions of the medulla
Adam J Prus et al.
Pharmacology, biochemistry, and behavior, 91(1), 150-154 (2008-07-23)
The Lewis (LEW) strain of rat appears more sensitive to nicotine than other strains in self-administration, conditioned place preference, and drug discrimination behavioral studies. The present study sought to further evaluate the behavioral effects of chronic nicotine treatment in the
Anthony Renda et al.
BMC neuroscience, 15, 89-89 (2014-07-21)
Understanding the underlying causes of nicotine addiction will require a multidisciplinary approach examining the key molecular, cellular and neuronal circuit functional changes that drive escalating levels of nicotine self-administration. In this study, we examined whether mice pretreated with chronic nicotine
Jonathan D Raybuck et al.
Behavioral neuroscience, 122(5), 1166-1171 (2008-10-01)
Varenicline, a partial agonist for a4ss2 nicotinic acetylcholine receptors (nAChRs) and full agonist for a7 nAChRs, has been approved for the treatment of smoking cessation. Although recent clinical trials support the efficacy of varenicline for managing global nicotine withdrawal symptoms
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.